Latest tumor Stories
MADRID, April 14, 2015 /PRNewswire/ -- - Combination of the anticancer drug PM1183 with PARP inhibitors and doxorubicin results in a synergistic
Study Results Featured in Plenary Session at Society of Gynecologic Oncology Annual Meeting IRVING, Texas, March 30, 2015 /PRNewswire/ -- Caris Life Sciences® today announced the
Research Presented at the Society of Gynecologic Oncology 2015 Annual Meeting Suggest Treatment Options Based on Biomarker Profile May Result in Improved Outcomes IRVING, Texas, March
Research Provides Potential Implications for Immunotherapy in Treatment of Gynecologic Cancers IRVING, Texas, March 29, 2015 /PRNewswire/ -- Caris Life Sciences® today announced the
Study Results Highlight Molecular Similarities and Differences between Uterine Papillary and Ovarian Serous Carcinomas, and between Epithelial Ovarian and Endometrial Cancers IRVING,
Will it be possible in the future to diagnose cancer without the need for a biopsy?
Study Using Caris Molecular Intelligence's Multiplatform Profiling Service Highlighted in Plenary Session at Society of Surgical Oncology Symposium IRVING, Texas, March 27, 2015 /PRNewswire/
Patients Too Sick for Enrollment in Phase III Trial for Newly Diagnosed GBM BETHESDA, Md., March 27, 2015 /PRNewswire/ -- Northwest Biotherapeutics, Inc.
DALLAS, March 26, 2015 /PRNewswire/ -- According to a new market research report "Tumor Ablation Market by Procedure Volume, Technology (RF, Microwave, Cryoablation, Others),
Researchers have developed an experimental drug to treat brain tumors by targeting the mitochondria. While it went well in mice, human trials are expected to happen very soon.
- A hairdresser.